CTRI/2022/09/045482尚未招募3 期
ââ?¬Å?The Efficacy and Safety of Thalidomide versus Azathioprine in Erythema Nodosum Leprosum (ENL): A Randomized Controlled Trialââ?¬?
Deepak Kumar Sahu0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •i.Patients with severe ENL of any gender and age >18 years.
- •ii.Patients willing to participate and willing to follow up for nine months
排除标准
- •i.Patients with known immunosuppression
- •ii.Patients with severe ENL on any steroid-sparing agents within the last one month
- •iii.Pregnancy and lactation
- •iv.Patients with a history of hypersensitivity to thalidomide or azathioprine
- •v.Patients with hemoglobin less than 10 gm/dl
- •vi.Patients with HIV, Hepatitis B and C infection.
- •vii.Patients who will deny giving consent to the study
研究者
相似试验
已完成
3 期
Effect of Thalidomide in Covid 19 pneumoniaPneumonia caused by Coronavirus 2019, COVID19.Coronavirus infection, unspecifiedB34.2IRCT20200428047232N1Esfahan University of Medical Sciences60
尚未招募
2 期
OW DOSE THALIDOMIDE VERSUS HYDROXYUREA IN TRANSFUSION DEPENDENT THALASSEMIA PATIENTSCTRI/2020/05/025142ALKA RANI KHADWA
尚未招募
3 期
se of medicines- Hydroxyurea and thalidomide for children suffering from thalassemiaCTRI/2023/12/060945ICMR, Delhi
进行中（未招募）
1 期
Efficacy of thalidomide in the treatment of heavy and frequent nose bleeding in patients affected by hereditary hemorrhagic telangiectasiaSevere recurrent epistaxis in hereditary hemorrhagic telangiectasiaMedDRA version: 14.1Level: LLTClassification code 10038554Term: Rendu-Osler-Weber syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-004096-36-ITOSPEDALE POLICLINICO S. MATTEO31
进行中（未招募）
不适用
Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002POEMS SYNDROMEMedDRA version: 9.1Level: SOCClassification code 10029205EUCTR2008-003202-33-ITISTITUTO CLINICO HUMANITAS